MGTX MeiraGTx Holdings plc

18.58
-0.29  -2%
Previous Close 18.87
Open 18.89
Price To Book 5.25
Market Cap 679,457,854
Shares 36,569,314
Volume 23,322
Short Ratio
Av. Daily Volume 163,481

NewsSee all news

  1. MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

    LONDON and NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company's

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced August 7, 2019.
AAV-AQP1
Xerostomia
Phase 1/2 data released May 14, 2019 - met primary endpoint of safety and tolerability.
AAV-RPE65
RPE65-Deficiency
Phase 1/2 trial ongoing.
AAV-RPGR
X-Linked Retinitis Pigmentosa
Phase 1/2 trial initiation announced August 7, 2019.
AAV-CNGA3
Achromatopsia
Phase 1/2 trial ongoing.
AAV-CNGB3
Achromatopsia

Latest News

  1. MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

    LONDON and NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company's